Selected research
Industry Research
Respiratory Virus Infection Drugs Industry Research Report 2026
Market perspective
The global Respiratory Virus Infection Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Respiratory Virus Infection Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Respiratory Virus Infection Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Respiratory Virus Infection Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Respiratory Virus Infection Drugs include Teva Pharmaceutical Industries Ltd., Sanofi, Merck and Co., Inc., GlaxoSmithKline plc, AstraZeneca, Orion Corporation, F. Hoffmann-La Roche Ltd., Cipla, Inc. and CHIESI Farmaceutici S.p.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Respiratory Virus Infection Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Respiratory Virus Infection Drugs Market by Company
Teva Pharmaceutical Industries Ltd.
Sanofi
Merck and Co., Inc.
GlaxoSmithKline plc
AstraZeneca
Orion Corporation
F. Hoffmann-La Roche Ltd.
Cipla, Inc.
CHIESI Farmaceutici S.p.A.
Boehringer Ingelheim International GmbH
Respiratory Virus Infection Drugs Segment by Type
Nasal Decongestants
Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
Antibiotics
Cough Suppressants
Others
Respiratory Virus Infection Drugs Segment by Application
Retail Pharmacies
Drug Stores
Hospital Pharmacies
Clinics
Others
Respiratory Virus Infection Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Virus Infection Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Virus Infection Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Virus Infection Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Respiratory Virus Infection Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Respiratory Virus Infection Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Respiratory Virus Infection Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nasal Decongestants
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Antibiotics
- Cough Suppressants
- Others
Applications
- Retail Pharmacies
- Drug Stores
- Hospital Pharmacies
- Clinics
- Others
Companies covered
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Merck and Co., Inc.
- GlaxoSmithKline plc
- AstraZeneca
- Orion Corporation
- F. Hoffmann-La Roche Ltd.
- Cipla, Inc.
- CHIESI Farmaceutici S.p.A.
- Boehringer Ingelheim International GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Respiratory Virus Infection Drugs Market Size (2021-2032)
- 2.2.2 Global Respiratory Virus Infection Drugs Sales (2021-2032)
- 2.2.3 Global Respiratory Virus Infection Drugs Market Average Price (2021-2032)
- 2.3 Respiratory Virus Infection Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nasal Decongestants
- 2.3.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- 2.3.4 Antibiotics
- 2.3.5 Cough Suppressants
- 2.3.6 Others
- 2.4 Respiratory Virus Infection Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Drug Stores
- 2.4.4 Hospital Pharmacies
- 2.4.5 Clinics
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Respiratory Virus Infection Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Respiratory Virus Infection Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Respiratory Virus Infection Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Respiratory Virus Infection Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Respiratory Virus Infection Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Respiratory Virus Infection Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Respiratory Virus Infection Drugs, Product Type & Application
- 3.8 Global Manufacturers of Respiratory Virus Infection Drugs, Established Date
- 3.9 Global Respiratory Virus Infection Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical Industries Ltd.
- 4.1.1 Teva Pharmaceutical Industries Ltd. Company Information
- 4.1.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 4.1.3 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Industries Ltd. Respiratory Virus Infection Drugs Product Portfolio
- 4.1.5 Teva Pharmaceutical Industries Ltd. Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Respiratory Virus Infection Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Merck and Co., Inc.
- 4.3.1 Merck and Co., Inc. Company Information
- 4.3.2 Merck and Co., Inc. Business Overview
- 4.3.3 Merck and Co., Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck and Co., Inc. Respiratory Virus Infection Drugs Product Portfolio
- 4.3.5 Merck and Co., Inc. Recent Developments
- 4.4 GlaxoSmithKline plc
- 4.4.1 GlaxoSmithKline plc Company Information
- 4.4.2 GlaxoSmithKline plc Business Overview
- 4.4.3 GlaxoSmithKline plc Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline plc Respiratory Virus Infection Drugs Product Portfolio
- 4.4.5 GlaxoSmithKline plc Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca Respiratory Virus Infection Drugs Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 Orion Corporation
- 4.6.1 Orion Corporation Company Information
- 4.6.2 Orion Corporation Business Overview
- 4.6.3 Orion Corporation Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Orion Corporation Respiratory Virus Infection Drugs Product Portfolio
- 4.6.5 Orion Corporation Recent Developments
- 4.7 F. Hoffmann-La Roche Ltd.
- 4.7.1 F. Hoffmann-La Roche Ltd. Company Information
- 4.7.2 F. Hoffmann-La Roche Ltd. Business Overview
- 4.7.3 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 F. Hoffmann-La Roche Ltd. Respiratory Virus Infection Drugs Product Portfolio
- 4.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 4.8 Cipla, Inc.
- 4.8.1 Cipla, Inc. Company Information
- 4.8.2 Cipla, Inc. Business Overview
- 4.8.3 Cipla, Inc. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Cipla, Inc. Respiratory Virus Infection Drugs Product Portfolio
- 4.8.5 Cipla, Inc. Recent Developments
- 4.9 CHIESI Farmaceutici S.p.A.
- 4.9.1 CHIESI Farmaceutici S.p.A. Company Information
- 4.9.2 CHIESI Farmaceutici S.p.A. Business Overview
- 4.9.3 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CHIESI Farmaceutici S.p.A. Respiratory Virus Infection Drugs Product Portfolio
- 4.9.5 CHIESI Farmaceutici S.p.A. Recent Developments
- 4.10 Boehringer Ingelheim International GmbH
- 4.10.1 Boehringer Ingelheim International GmbH Company Information
- 4.10.2 Boehringer Ingelheim International GmbH Business Overview
- 4.10.3 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Boehringer Ingelheim International GmbH Respiratory Virus Infection Drugs Product Portfolio
- 4.10.5 Boehringer Ingelheim International GmbH Recent Developments
5 Global Respiratory Virus Infection Drugs Market Scenario by Region
- 5.1 Global Respiratory Virus Infection Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Respiratory Virus Infection Drugs Sales by Region: 2021-2032
- 5.2.1 Global Respiratory Virus Infection Drugs Sales by Region: 2021-2026
- 5.2.2 Global Respiratory Virus Infection Drugs Sales by Region: 2027-2032
- 5.3 Global Respiratory Virus Infection Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Respiratory Virus Infection Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Respiratory Virus Infection Drugs Revenue by Region: 2027-2032
- 5.4 North America Respiratory Virus Infection Drugs Market Facts & Figures by Country
- 5.4.1 North America Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Respiratory Virus Infection Drugs Sales by Country (2021-2032)
- 5.4.3 North America Respiratory Virus Infection Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Respiratory Virus Infection Drugs Market Facts & Figures by Country
- 5.5.1 Europe Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Respiratory Virus Infection Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Respiratory Virus Infection Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Respiratory Virus Infection Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Respiratory Virus Infection Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Respiratory Virus Infection Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Respiratory Virus Infection Drugs Market Facts & Figures by Country
- 5.7.1 South America Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Respiratory Virus Infection Drugs Sales by Country (2021-2032)
- 5.7.3 South America Respiratory Virus Infection Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Respiratory Virus Infection Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Respiratory Virus Infection Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Respiratory Virus Infection Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Respiratory Virus Infection Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Respiratory Virus Infection Drugs Sales by Type (2021-2032)
- 6.1.1 Global Respiratory Virus Infection Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Respiratory Virus Infection Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Respiratory Virus Infection Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Respiratory Virus Infection Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Respiratory Virus Infection Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Respiratory Virus Infection Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Respiratory Virus Infection Drugs Sales by Application (2021-2032)
- 7.1.1 Global Respiratory Virus Infection Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Respiratory Virus Infection Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Respiratory Virus Infection Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Respiratory Virus Infection Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Respiratory Virus Infection Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Respiratory Virus Infection Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Respiratory Virus Infection Drugs Value Chain Analysis
- 8.1.1 Respiratory Virus Infection Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Respiratory Virus Infection Drugs Production Mode & Process
- 8.2 Respiratory Virus Infection Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Respiratory Virus Infection Drugs Distributors
- 8.2.3 Respiratory Virus Infection Drugs Customers
9 Global Respiratory Virus Infection Drugs Analyzing Market Dynamics
- 9.1 Respiratory Virus Infection Drugs Industry Trends
- 9.2 Respiratory Virus Infection Drugs Industry Drivers
- 9.3 Respiratory Virus Infection Drugs Industry Opportunities and Challenges
- 9.4 Respiratory Virus Infection Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst